Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone in Nonsuicidal Self-injurious Behavior
NCT06622239Phase 2Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone in nonsuicidal self-injury (NSSI) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Frequency of nonsuicidal self-injurious behavior at 6 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
naltrexone
03
Conditions
nonsuicidal self-injury (NSSI)
Beyond the preview
Go deeper on NCT06622239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622239.